Harrow, Inc. (HROW)
| Market Cap | 1.51B |
| Revenue (ttm) | 272.30M |
| Net Income (ttm) | -5.14M |
| Shares Out | 37.23M |
| EPS (ttm) | -0.14 |
| PE Ratio | n/a |
| Forward PE | 91.29 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 436,727 |
| Open | 41.20 |
| Previous Close | 41.41 |
| Day's Range | 39.87 - 41.47 |
| 52-Week Range | 21.12 - 54.85 |
| Beta | 0.31 |
| Analysts | Strong Buy |
| Price Target | 69.86 (+72.62%) |
| Earnings Date | May 11, 2026 |
About HROW
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE, as well as BYQLOVI; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for p... [Read more]
Financial Performance
In 2025, Harrow's revenue was $272.30 million, an increase of 36.41% compared to the previous year's $199.61 million. Losses were -$5.14 million, -70.60% less than in 2024.
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for HROW stock is "Strong Buy." The 12-month stock price target is $69.86, which is an increase of 72.62% from the latest price.
News
Harrow To Report First Quarter 2026 Financial Results After Market Close on May 11, 2026
NASHVILLE, Tenn., April 27, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it will report its fina...
Harrow Announces the Issuance of J-Code for IOPIDINE® 1%
NASHVILLE, Tenn., April 16, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that IOPIDINE® 1% (apracloni...
LogiCare3PL Selected as Distribution Partner by Harrow
OLIVE BRANCH, Miss., April 14, 2026 /PRNewswire/ -- LogiCare3PL today announced it has been selected by Harrow, Inc. (Nasdaq: HROW) as a distribution partner for Harrow's portfolio of ophthalmic disea...
Harrow Announces Pricing of $50.0 Million Offering of Senior Unsecured Notes Due 2030
NASHVILLE, Tenn., March 24, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the pricing of its private o...
Harrow Announces Add-On Offering of $50.0 Million of Senior Unsecured Notes to Support Growth
NASHVILLE, Tenn., March 24, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it intends to offer, su...
Harrow Announces Three Abstracts Accepted for Presentation at ASCRS 2026 Annual Meeting
NASHVILLE, Tenn., March 18, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that three scientific abstra...
Harrow Transcript: Leerink Global Healthcare Conference 2026
Strong five-year growth continues with record revenues and EBITDA, driven by a diverse ophthalmic portfolio and new product launches. Key products like VEVYE, IHEEZO, and TRIESENCE are expanding market share, while biosimilars and pipeline assets support future growth.
These Analysts Revise Their Forecasts On Harrow Following Q4 Results
Harrow Inc. (NASDAQ: HROW) posted mixed results for the fourth quarter on Tuesday.
Harrow to Present at Leerink Partner's 2026 Global Healthcare Conference
NASHVILLE, Tenn., March 04, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that management will present...
Harrow Earnings Call Transcript: Q4 2025
Delivered 36% revenue growth in 2025, driven by strong performance across VEVYE, IHEEZO, and TRIESENCE, with expanded sales forces and new product launches expected to accelerate growth in 2026. Guidance calls for $350M–$365M revenue and $80M–$100M adjusted EBITDA.
Harrow to Initiate Phase 3 Clinical Trial Seeking to Expand TRIESENCE® Label to Include Ocular Inflammation and Pain Following Cataract Surgery Indication
NASHVILLE, Tenn., March 03, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that the U.S. Food and Drug ...
Harrow Announces Q4 and Full-Year 2025 Financial Results and 2026 Financial Guidance
Fourth Quarter, Full-Year 2025 and Selected Highlights: Record quarterly revenue of $89.1 million, a 33% increase over $66.8 million recorded in the prior-year period Full-Year revenue of $272.3 mill...
Harrow To Report Fourth Quarter and Year-End 2025 Financial Results After Market Close on March 2, 2026
NASHVILLE, Tenn., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it will report its finan...
Harrow Announces Cash-Pay Direct-to-Prescriber PharmaPack™ Kits
NASHVILLE, Tenn., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the launch of a new Direct-to...
Harrow Reaffirms 2025 Full-Year Revenue Guidance of $270–$280 Million, Marking Another Year of Strong Growth
Doubling of VEVYE® Sales Force is On Track, Expansion of IHEEZO® Commercial Footprint to the Office-Based Setting Underway, and Doubling TRIESENCE® Commercial Footprint in the Surgical-Based Setting ...
Harrow Transcript: Piper Sandler 37th Annual Healthcare Conference
Recent acquisition of Melt expands sedation opportunities beyond ophthalmology, with MELT-300 and MELT-210 targeting large, underserved markets. VEVYE and IHEEZO are driving growth through improved access and product differentiation, while biosimilar launches in 2026–2027 aim to leverage integrated solutions in retina care.
Harrow to Present at Two Investor Conferences in December
NASHVILLE, Tenn., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that management will particip...
Harrow Announces Closing of Acquisition of Melt Pharmaceuticals
NASHVILLE, Tenn., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has completed the acq...
Harrow Earnings Call Transcript: Q3 2025
Q3 revenue rose 45% year-over-year to $71.6M, led by strong growth in VEVYE and IHEEZO. Full-year guidance was updated to $270–$280M, with VEVYE set for a major boost from new PBM coverage in 2026. Four new product launches and the Melt Pharmaceuticals acquisition are key growth drivers.
Harrow Announces Third Quarter 2025 Financial Results
Third-Quarter 2025 and Recent Selected Highlights: Total revenues of $71.6 million, a 45% increase over $49.3 million recorded in the prior-year period GAAP net income of $1.0 million Adjusted EBITDA...
Harrow To Report Third Quarter 2025 Financial Results After Market Close on November 10, 2025
Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on November 11, 2025 Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on November 11, 2025
ImprimisRx Announces Leadership Changes
Frank Mullery Appointed Chief Executive Officer of ImprimisRx Bridseida Cruz Appointed Head of Quality of ImprimisRx NASHVILLE, Tenn., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leadin...
Harrow Transcript: Investor Day 2025
A founder-led ophthalmic company is executing a disciplined growth strategy, leveraging M&A, innovative access programs, and a broad product pipeline to target leadership in dry eye, retina, and surgical markets. Financial guidance targets $280M+ revenue in 2025 and $250M+ quarterly by Q4 2027, with new launches and biosimilars as key drivers.
Harrow to Acquire Melt Pharmaceuticals
NASHVILLE, Tenn., Sept. 26, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has entered into an ...
Harrow Launches Harrow Access for All (HAFA)
HAFA to Expand Harrow's Innovative Market Access Model Across Ophthalmic Portfolio Program will be available in late 2025 through the HarrowAccess.com Portal NASHVILLE, Tenn., Sept. 25, 2025 (GLOBE NE...